The newly approved editions to the C2 Therapeutics portfolio are designed to treat Barrett’s esophagus.
“The U.S. regulatory clearance of the promising Coldplay Full and Swipe Ablation Systems is a major leap forward in the care of patients with Barrett’s Esophagus at risk for development of esophageal cancer,” said George Triadafilopoulos, MD, clinical professor of gastroenterology and hepatology at Stanford (Calif.) University. “These technologies provide endoscopists with more options to eliminate Barrett’s Esophagus and improve patient outcomes.”
More articles on gastroenterology:
GI physician leader to know: Dr. Lewis Strong of Centers for Gastroenterology
FDA clears 2 new HCV drugs
170 GI physicians making headlines in 2015 so far
